Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Since 2016 both digestive neuroendocrine neoplasms (D-NENs) and non-digestive NENs (ND-NENs) cases are treated within NETwerk, an ENETS Center of Excellence
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Vandamme T, De Backer L, Dero I, Galdermans D, Abrams P,
Keywords: non-digestive NENs, gastroenteropancreatic NENs,
Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Braat A
Authors: Braat A, Kappadath C, Ahmadzadehfar H, Stothers C, Deroose C,
Keywords: PRRT, Radioembolization, neuroendocrine tumors, metastasis, radionuclide treatments,
Introduction: A multi-institutional health network (nine hospitals) was set up in the Belgian Antwerp-Waasland region for the multidisciplinary care of gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients, called “NETwerk”. Local multidisciplinary teams refer all GEP-NET patients to be discussed among specialists, experienced in NET diagnostics and treatment, at a NET specific multidisciplinary tumorboard (MDT).
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Peeters M
Authors: Lybaert W, Vandamme T, Simoens M, Dero I, Demey W,
Keywords: care networks, quality,
Introduction: Radioembolization (RE) is applied worldwide in patients with liver-dominant metastatic neuroendocrine tumours (mNET). Current literature is of poor quality and based on small heterogeneous populations
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Braat A
Authors: Braat A, Mahvash A, Stothers C, Deroose C, Frilling A,
Keywords: neuroendocrine tumors, radioembolization, sirt,
Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: VAN BINNEBEEK S
Authors: Van Binnebeek S, DeRoose C, Van Billoen B, Baete K, Mortelmans L,
Keywords: antibody, somatostatin analogue, 90Y-DOTATOC, dosimetry, PRRT, 68Ga-DOTATOC,